• A multiplexed in vivo approach to identify driver genes in small cell lung cancer.

A multiplexed in vivo approach to identify driver genes in small cell lung cancer.

Cell reports (2023-01-15)
Myung Chang Lee, Hongchen Cai, Christopher W Murray, Chuan Li, Yan Ting Shue, Laura Andrejka, Andy L He, Alessandra M E Holzem, Alexandros P Drainas, Julie H Ko, Garry L Coles, Christina Kong, Shirley Zhu, ChunFang Zhu, Jason Wang, Matt van de Rijn, Dmitri A Petrov, Monte M Winslow, Julien Sage

Small cell lung cancer (SCLC) is a lethal form of lung cancer. Here, we develop a quantitative multiplexed approach on the basis of lentiviral barcoding with somatic CRISPR-Cas9-mediated genome editing to functionally investigate candidate regulators of tumor initiation and growth in genetically engineered mouse models of SCLC. We found that naphthalene pre-treatment enhances lentiviral vector-mediated SCLC initiation, enabling high multiplicity of tumor clones for analysis through high-throughput sequencing methods. Candidate drivers of SCLC identified from a meta-analysis across multiple human SCLC genomic datasets were tested using this approach, which defines both positive and detrimental impacts of inactivating 40 genes across candidate pathways on SCLC development. This analysis and subsequent validation in human SCLC cells establish TSC1 in the PI3K-AKT-mTOR pathway as a robust tumor suppressor in SCLC. This approach should illuminate drivers of SCLC, facilitate the development of precision therapies for defined SCLC genotypes, and identify therapeutic targets.

Product Number
Product Description

Anti-UCHL1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution